SK286900B6 - Spôsob prípravy rekombinantných vírusov a rekombinantný vírus - Google Patents

Spôsob prípravy rekombinantných vírusov a rekombinantný vírus Download PDF

Info

Publication number
SK286900B6
SK286900B6 SK666-99A SK66699A SK286900B6 SK 286900 B6 SK286900 B6 SK 286900B6 SK 66699 A SK66699 A SK 66699A SK 286900 B6 SK286900 B6 SK 286900B6
Authority
SK
Slovakia
Prior art keywords
baculovirus
genome
recombinant
region
defective
Prior art date
Application number
SK666-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK66699A3 (en
Inventor
H�L�Ne Leblois-Prehaud
Michel Perricaudet
Emmanuelle Vigne
Patrice Yeh
Original Assignee
Gencell Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9497899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286900(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gencell Sa filed Critical Gencell Sa
Publication of SK66699A3 publication Critical patent/SK66699A3/sk
Publication of SK286900B6 publication Critical patent/SK286900B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pens And Brushes (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SK666-99A 1996-11-22 1997-11-18 Spôsob prípravy rekombinantných vírusov a rekombinantný vírus SK286900B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9614278A FR2756297B1 (fr) 1996-11-22 1996-11-22 Procede de production de virus recombinants
PCT/FR1997/002073 WO1998022607A1 (fr) 1996-11-22 1997-11-18 Procede de production de virus recombinants

Publications (2)

Publication Number Publication Date
SK66699A3 SK66699A3 (en) 2000-02-14
SK286900B6 true SK286900B6 (sk) 2009-07-06

Family

ID=9497899

Family Applications (1)

Application Number Title Priority Date Filing Date
SK666-99A SK286900B6 (sk) 1996-11-22 1997-11-18 Spôsob prípravy rekombinantných vírusov a rekombinantný vírus

Country Status (18)

Country Link
US (2) US6387670B1 (pt)
EP (1) EP0946741B1 (pt)
JP (1) JP4686670B2 (pt)
KR (1) KR100719645B1 (pt)
AT (1) ATE317908T1 (pt)
AU (1) AU731106B2 (pt)
BR (1) BR9713388B1 (pt)
CA (1) CA2271438C (pt)
CZ (1) CZ293947B6 (pt)
DE (1) DE69735274T2 (pt)
ES (1) ES2260803T3 (pt)
FR (1) FR2756297B1 (pt)
HU (1) HU224713B1 (pt)
IL (1) IL129686A (pt)
NO (2) NO323937B1 (pt)
SK (1) SK286900B6 (pt)
WO (1) WO1998022607A1 (pt)
ZA (1) ZA9710516B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6793926B1 (en) * 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
CA2375119A1 (en) * 1999-05-27 2000-12-07 Genovo, Incorporated Compositions and methods for production of recombinant virus using a carrier vector derived from a nonmammalian virus
AU5448400A (en) * 1999-05-28 2000-12-18 Mount Sinai School Of Medicine, The A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
GB9919409D0 (en) 1999-08-18 1999-10-20 Univ Oxford Brookes Baculovirus expression system
CA2494772C (en) 2002-08-29 2015-12-01 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
GB0702694D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Vectors
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2249950B1 (en) * 2008-03-05 2014-10-15 Council of Scientific & Industrial Research A polymeric hybrid membrane
EP2287323A1 (en) 2009-07-31 2011-02-23 Association Institut de Myologie Widespread gene delivery to the retina using systemic administration of AAV vectors
EP2292781A1 (en) 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
WO2011123088A1 (en) * 2010-04-01 2011-10-06 Weidong Xiao Compositions and methods for the production of recombinant virus vectors
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US9677088B2 (en) 2012-05-09 2017-06-13 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
US20150182637A1 (en) 2012-06-21 2015-07-02 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
WO2015031686A1 (en) 2013-08-30 2015-03-05 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
SG10201810150UA (en) 2014-03-17 2018-12-28 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
CN107405507B (zh) 2015-03-02 2022-05-03 阿德夫拉姆生物技术股份有限公司 用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
EP3716990A4 (en) 2017-11-27 2021-12-08 Coda Biotherapeutics, Inc. COMPOSITIONS AND PROCEDURES FOR NEUROLOGICAL DISEASES
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
EP3755795A4 (en) 2018-02-19 2022-07-20 Homology Medicines, Inc. ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RECOVERING F8 GENE FUNCTION AND METHODS OF USE THEREOF
CN113924115A (zh) 2019-01-31 2022-01-11 俄勒冈健康与科学大学 用于aav衣壳的使用转录依赖性定向进化的方法
CA3151920A1 (en) 2019-08-21 2021-02-25 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
WO2023212298A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Bispecific antibodies and methods of treating ocular disease
WO2023212294A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Angiopoietin-related protein 7-specific antibodies and uses thereof
WO2023212293A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Complement factor h related 4-specific antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92298A (en) * 1988-11-14 2001-04-30 Us Secretary U S Dept Of Comme Method for producing isolated empty b19 parvovirus capsids, introducing genes into cells utilizing the same, diagnostic assays for detecting parvovirus infection and an anti-parvovirus vaccine containing said capsids
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO1996009074A1 (en) * 1994-09-23 1996-03-28 The General Hospital Corporation Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell

Also Published As

Publication number Publication date
AU5226198A (en) 1998-06-10
CZ293947B6 (cs) 2004-08-18
FR2756297A1 (fr) 1998-05-29
JP2001503993A (ja) 2001-03-27
EP0946741B1 (fr) 2006-02-15
SK66699A3 (en) 2000-02-14
NO2013009I1 (no) 2013-04-29
KR100719645B1 (ko) 2007-05-17
HUP0001762A3 (en) 2002-01-28
HUP0001762A2 (hu) 2000-09-28
ATE317908T1 (de) 2006-03-15
CA2271438A1 (fr) 1998-05-28
BR9713388B1 (pt) 2009-01-13
US6387670B1 (en) 2002-05-14
EP0946741A1 (fr) 1999-10-06
CA2271438C (fr) 2010-10-26
IL129686A0 (en) 2000-02-29
NO992464D0 (no) 1999-05-21
BR9713388A (pt) 2000-03-21
JP4686670B2 (ja) 2011-05-25
KR20000057202A (ko) 2000-09-15
FR2756297B1 (fr) 1999-01-08
HU224713B1 (en) 2006-01-30
DE69735274T2 (de) 2006-10-12
IL129686A (en) 2005-12-18
DE69735274D1 (de) 2006-04-20
ES2260803T3 (es) 2006-11-01
AU731106B2 (en) 2001-03-22
WO1998022607A1 (fr) 1998-05-28
US20030022356A1 (en) 2003-01-30
ZA9710516B (en) 1998-06-10
CZ182299A3 (cs) 1999-08-11
NO992464L (no) 1999-06-23
NO323937B1 (no) 2007-07-23

Similar Documents

Publication Publication Date Title
US6387670B1 (en) Method for producing recombinant virus
EP1226264B1 (en) Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus
US6878549B1 (en) Packaging systems for human recombinant adenovirus to be used in gene therapy
JP4190028B2 (ja) 欠陥組換えアデノウイルスベクター及び遺伝子治療での使用
SK174297A3 (en) Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses
SK99097A3 (en) Cells for the production of recombinant adenoviruses
US20090098599A1 (en) Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
JP2002526031A (ja) 機能的ゲノム適用にライブラリーを使用される遺伝子機能に関する高度処理能力スクリーニング法
AU2437200A (en) Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
MXPA99004449A (en) Method for producing recombinant virus
AU7560500A (en) Modified adenoviral vectors for use in gene therapy
EP1083228A1 (en) Modified adenoviral vectors for use in gene therapy

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: CENTELION, VITRY SUR SEINE, FR

Effective date: 20110120

TB4A Correction of name

Owner name: CENTELION (SAS), VITRY SUR SEINE, FR

PC4A Assignment and transfer of rights

Owner name: AVENTIS PHARMA S.A., ANTONY, FR

Free format text: FORMER OWNER: CENTELION (SAS), VITRY SUR SEINE, FR

Effective date: 20130701

Owner name: SANOFI, PARIS, FR

Free format text: FORMER OWNER: AVENTIS PHARMA S.A., ANTONY, FR

Effective date: 20130401

SPCF Filing of an spc

Free format text: PRODUCT NAME: ALIPOGEN TIPARVOVEK; REGISTRATION NO/DATE: EU/1/12/791/001 20121025

Spc suppl protection certif: 5009-2013

Filing date: 20130423

MK4A Patent expired

Expiry date: 20171118